title: Associations of adiponectin with metabolic and vascular risk parameters in the British Regional Heart Study reveal stronger links to insulin resistance-related than to coronory heart disease risk-related parameters.
abstract: OBJECTIVE
  Adiponectin is considered by many to be part of the 'common soil' linking type 2 diabetes and coronary heart disease (CHD). We examined the relationship between adiponectin and insulin resistance, metabolic, inflammatory and haemostatic risk factors and hepatic function.
  
  
  RESULTS
  The study was carried out in 3640 non-diabetic men aged 60-79 years drawn from general practices in 24 British towns and who were not on warfarin. Adiponectin was associated with waist circumference (inversely), alcohol intake (positively) and physical activity (nonlinearly); no association was seen with cigarette smoking, prevalent CHD or stroke. After adjustment for these factors, adiponectin was significantly inversely associated with insulin resistance, triglyceride, C-reactive protein (but not interleukin 6), tissue plasminogen activator and alanine aminotransferase and positively associated with high-density lipoprotein cholesterol (HDL-cholesterol) and Factor VIII, factors associated with diabetes. No association was seen with cholesterol, smoking, systolic blood pressure or coagulation factors. Risk of the metabolic syndrome decreased significantly with increasing adiponectin.
  
  
  CONCLUSIONS
  Adiponectin is inversely associated with factors strongly associated with the development of diabetes. Limited associations with the established major risk factors for CHD suggest adiponectin may be a stronger marker of risk for diabetes than for CHD.
authors.affiliation: Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK. goya@pcps.ucl.ac.uk
authors.forename: S G
authors.initials: SG
authors.lastname: Wannamethee
authors.forename: J
authors.initials: J
authors.lastname: Tchernova
authors.forename: P
authors.initials: P
authors.lastname: Whincup
authors.forename: G D
authors.initials: GD
authors.lastname: Lowe
authors.forename: A
authors.initials: A
authors.lastname: Rumley
authors.forename: K
authors.initials: K
authors.lastname: Brown
authors.forename: L
authors.initials: L
authors.lastname: Cherry
authors.forename: N
authors.initials: N
authors.lastname: Sattar
mesh_terms: D052242:Adiponectin / Q000097:blood; D000328:Adult; D015992:Body Mass Index; D002097:C-Reactive Protein / Q000378:metabolism; D008076:Cholesterol, HDL / Q000097:blood; D003327:Coronary Disease / Q000097:blood / Q000453:epidemiology*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000453:epidemiology*; D004730:Endothelium, Vascular / Q000378:metabolism; D005169:Factor VIII / Q000378:metabolism; D006801:Humans; D007249:Inflammation / Q000097:blood / Q000453:epidemiology; D007333:Insulin Resistance; D008099:Liver / Q000378:metabolism; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood / Q000453:epidemiology*; D008875:Middle Aged; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood; D006113:United Kingdom / Q000453:epidemiology
chemical_list: C499918:ADIPOQ protein, human; D052242:Adiponectin; D008076:Cholesterol, HDL; D014280:Triglycerides; D005169:Factor VIII; D002097:C-Reactive Protein